Substituted nucleosides, nucleotides and analogs thereof

Patent metadata

Field	Value
Publication number	US-12173025-B2
Application number	US-202217836763-A
Country	US
Kind code	B2
Filing date	Jun 9, 2022
Priority date	Dec 21, 2012
Publication date	Dec 24, 2024
Grant date	Dec 24, 2024

Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

First claim

What is claimed is:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

wherein:
B 1 is an optionally substituted

R 1 is an optionally substituted C 1-6 alkyl;
R 2 is halo or —OR 7A ;
R 3 is O;
Z p is O;
R p1 is an —O-optionally substituted C 1-6 alkyl;
R 6C is an unsubstituted C 1-6 alkyl, and
R 7A is hydrogen.

2. The compound of claim 1 , wherein R 2 is halo.

3. The compound of claim 2 , wherein R 2 is fluoro.

4. The compound of claim 1 , wherein R 2 is-OR 7A .

5. The compound of claim 4 , wherein R 7A is hydrogen.

6. The compound of claim 1 , wherein R 1 is an optionally substituted ethyl.

7. The compound of claim 6 , having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

8. The compound of claim 7 , having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

Assignees

• Janssen Pharmaceuticals Inc

Inventors

• Beigelman Leonid
• Wang Guangyi
• Smith David Bernard

Classifications

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title

• C07H19/207

  the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide · CPC title

• C07H19/16

  Purine radicals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07H19/213 Primary

  containing cyclic phosphate · CPC title